Curis Lifesciences IPO Review & Recommendations

Curis Lifesciences IPO Peer Comparison

Curis Lifesciences Limited peer comparison with similar listed entities. (As on March 31, 2024)

Notes:

• Source - All the financial information for listed industry peers mentioned above is sourced from the published results of the aforesaid companies for the year ended March 31, 2025 and stock exchange data dated 31/03/2025 to compute the corresponding financial ratios. For our Company, current market price and PE ratio of our company will be determined at the end of book building process. For peer companies, P/E Ratio is based on the market price as on March 28, 2025 and March 28, 2025 for Sotac Pharmaceuticals Limited and Lincoln Pharmaceuticals Limited, respectively.
• The EPS, NAV, RoNW and total Income of our Company are taken as per Restated Financial Statement for the Financial Year 2023-24.
• NAV per share of our company is computed as the closing net worth divided by the weighted average number of paid up equity shares as on March 31, 2024. NAV per share of peers company is computed as the closing net worth divided by the weighted average number of paid up equity shares as on March 31, 2025.
• RoNW has been computed as net profit after tax divided by closing net worth.
• Net worth has been computed in the manner as specifies in Regulation 2(1)(hh) of SEBI (ICDR) Regulations, 2018.